Rational design of GRK2 inhibitors for the treatment of heart failure
2017-01-16 03:42JohnTESMERHelenWALDSCHMIDTMarieCATOReneeBOULEYOsvaldoCRUZRODRIGUEZScottLARSEN
中國藥理學(xué)與毒理學(xué)雜志 2017年10期
John J TESMER,Helen V WALDSCHMIDT,Marie C CATO,Renee BOULEY,Osvaldo CRUZ-RODRIGUEZ,Scott D LARSEN
(University of Michigan,1.Life Sciences Institute,3.Valteich Medicinal Chemistry Core,Ann Arbor Michigan 48109 USA;2.Department of Biological Sciences,Purdue University,West Lafayette Indiana 47907 USA)
- 中國藥理學(xué)與毒理學(xué)雜志的其它文章
- Pharmacological study on traditional Chinese medicine and natural product in China
- GPCRomics:tissue and cellular GPCR expression identifies new therapeutic targets
- Direction of new drug research:soft regulation of inflammatory immune responses
- Targeting Gprotein-coupled receptors for the treatment of autoimmune diseases
- Arrestin mediated GPCR biased signaling and its application in new drug discovery
- Identification of a novel target for cancer and anti-fibrotic therapy